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extensive aortoiliac occlusive disease
Vincent Jongkind, MD,a,b George J. M. Akkersdijk, MD,a Kak K. Yeung, MSc,b and
Willem Wisselink, MD,b Hoofddorp and Amsterdam, The Netherlands
Objectives: Current multidisciplinary guidelines recommend to treat extensive aortoiliac occlusive disease (AIOD) by
surgical revascularization. Surgery provides good long-term patency, but at the cost of substantial perioperative
morbidity. Development of new technologies and techniques has led to increased use of endovascular therapy for
extensive AIOD. We performed a systematic review of the literature to determine contemporary short- and long-term
results of endovascular therapy for extensive AIOD.
Methods: The Medline, Embase, and Cochrane databases were searched to identify all studies reporting endovascular
treatment of extensive AIOD (TransAtlantic Inter-Society Consensus (TASC) type C and D) from January 2000 to June
2009. Two independent observers selected studies for inclusion, assessed the methodologic quality of the included
studies, and performed the data extraction. Outcomes were technical success, clinical success, mortality, complications,
long-term primary, and secondary patency rates.
Results:Nineteen nonrandomized cohort studies reporting on 1711 patients were included. There was substantial clinical
heterogeneity between the studies considering study population and interventional techniques. Technical success was
achieved in 86% to 100% of the patients. Clinical symptoms improved in 83% to 100%. Mortality was described in seven
studies and ranged from 1.2% to 6.7%. Complications were reported in 3% to 45% of the patients. Most common
complications were distal embolization, access site hematomas, pseudoaneurysms, arterial ruptures, and arterial dissec-
tions. The majority of complications could be treated using percutaneous or noninvasive techniques. Four- or 5-year
primary and secondary patency rates ranged from 60% to 86% and 80% to 98%, respectively.
Conclusions: Endovascular treatment of extensive AIOD can be performed successfully by experienced interventionists in
selected patients. Although primary patency rates are lower than those reported for surgical revascularization, reinter-
ventions can often be performed percutaneously, with secondary patency comparable to surgical repair. ( J Vasc Surg
2010;52:1376-83.)Occlusive disease of the aorta and iliac arteries may lead
to incapacitating claudication or critical ischemia. Surgical
repair in the form of bypass grafting or endarterectomy has
proven effective in relieving symptoms and provides good
long-term patency. Perioperative morbidity, however, is
substantial.1-4 Endovascular techniques have been devel-
oped as a minimal invasive alternative in the treatment of
arterial occlusive disease with reduced morbidity compared
with surgical repair. In localized or focal aortoiliac occlusive
disease (AIOD) endovascular therapy using balloon angio-
plasty with or without placement of stents currently is the
treatment of choice.5-8
The TransAtlantic Inter-Society Consensus (TASC)
allows classification of AIOD by lesion morphology (Table
I).7,8 According to the multidisciplinary TASC guidelines,
published in 2007, endovascular therapy is the preferred
method of treatment for localized disease (TASC type A
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1376and B), while extensive disease (TASC type C andD) can be
best treated by reconstructive surgery.8 However, recent
device developments and increased experience of interven-
tionists have prompted the utilization of endovascular ther-
apy for extensive AIOD. The aim of the present study was
to perform a systematic review of contemporary relevant
literature on short- and long-term results of endovascular
therapy for extensive aortoiliac occlusive disease.
METHODS
A systematic review was performed according to the
guidelines of the Meta-analysis Of Observational Studies in
Epidemiology group (MOOSE) and the Dutch Cochrane
Centre.9,10
Search strategy. Two independent investigators (V.J.
and K.Y.) performed a computer-assisted search. The med-
ical databases Medline, Embase, and the Cochrane Data-
base of Systematic Reviews were searched (from January
2000 to June 2009), using a combination of the following
medical subject headings (MeSH): angioplasty, balloon
angioplasty, arterial occlusive diseases, arteriosclerosis, Le-
riche syndrome, abdominal aorta, and iliac artery. Addi-
tionally, a combination of the following free text words was
used: endovascular, arterial occlusive disease, occlusive dis-
ease, aorta, and iliac artery. Electronic links to related
articles and reference lists of selected articles were hand-
searched to retrieve more studies. A hand-search for rele-
mmon
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formed. A search was not done for unpublished data or
abstracts. Relevant studies were selected for full text review
based on title and abstract.
Study selection. Studies reporting on endovascular
therapy for extensive AIODwere selected based on full text
review by two independent authors (V.J. and K.Y.). To be
eligible, studies had to report the morphology of aortoiliac
occlusive lesions, preferably but not exclusively based upon
the TASC guidelines.7,8 Extensive AIOD was defined as
TASC type C or D lesions (Table I). Alternatively, guide-
lines of the Society of Cardiovascular and Interventional
Radiology (SCVIR) could be used for classification of
AIOD.11 SCVIR categories 3 and 4 for iliac artery and
aortic angioplasty were considered extensive AIOD (Table
I). Studies that did not use TASC or SCVIR classifications
could be included only if morphology of aortoiliac occlu-
sive lesions was accurately described, and extensive AIOD
could be assumed by both investigators. Studies reporting
combined results of localized and extensive AIOD were
eligible only if independent results of extensive AIOD
could be retrieved or if the majority of the lesions depicted
extensive disease. To provide a comprehensive overview all
studies reporting on endovascular treatment of extensive
Table I. TransAtlantic Inter-Society Consensus (TASC) a
(SCVIR) classifications8,11
TASC
type A
Unilateral or bilateral stenoses of CIA
Unilateral or bilateral single short (3 cm) stenosis of EIA
type B
Short (3 cm) stenosis of infrarenal aorta
Unilateral CIA occlusion
Single or multiple stenosis totaling 3-10 cm involving the
EIA not extending into the CFA
Unilateral EIA occlusion not involving the origins of
internal iliac or CFA
type C
Bilateral CIA occlusions
Bilateral EIA stenoses 3-10 cm long not extending into
the CFA
Unilateral EIA stenosis extending into the CFA
Unilateral EIA occlusion that involves the origins of
internal iliac and/or CFA
Heavily calcified unilateral EIA occlusion with or without
involvement of origins of internal iliac and/or CFA
type D
Infrarenal aortoiliac occlusion
Diffuse disease involving the aorta and both iliac arteries
Diffuse multiple stenoses involving the unilateral CIA,
EIA, and CFA
Unilateral occlusions of both CIA and EIA
Bilateral occlusions of EIA
Iliac stenoses in patients with AAA requiring treatment
and not amendable to endograft placement or other
lesions requiring open aortic or iliac surgery
AAA, Abdominal aortic aneurysm; CFA, common femoral artery; CIA, coAIOD were included, regardless of differences in theirmethods of intervention (ie, use of percutaneous or open
vascular access, use of thrombolysis, or performance of
additional surgical outflow procedures). These differences
were accounted for during analysis. Only studies published
in English or Dutch language were included. Articles had
to describe original patient series to be eligible. Studies
containing duplicate material were excluded. The larger
study, containing the best documented data, was included
for analysis. Review articles, technical descriptions, case
reports, and small patient series (N  10) were excluded.
Methodologic quality assessment. Two investiga-
tors (V.J. and K.Y.) independently assessed the method-
ologic quality of each included study using a critical review
checklist.9 Study quality was assessed in two ways. First, the
fulfillment of seven requirements was determined: a clear
definition of the study population, exclusion of selection
bias, clear description of method of intervention, detailed
description of outcome, data collection by independent or
blinded observers, no selective loss of patients to follow-up,
and description of confounders. Furthermore, all studies
were evaluated using a list of detailed study characteristics
as proposed by the MOOSE group.10 Each item was
graded on a scale of 0 to 2 depending on the information
available in the article. Quality score was determined by
ociety of Cardiovascular and Interventional Radiology
SCVIR
1
ort segment (2 cm) stenoses of the infrarenal aorta, with
minimal atherosclerosis of the aorta otherwise.
ac stenoses less than 3 cm in length that are concentric and
noncalcified.
2
4 cm stenoses of the infrarenal aorta, with mild atherosclerosis of
the aorta otherwise
ac stenoses 3-5 cm in length or calcified or eccentric stenoses less
than 3 cm in length
3
ng segment (4 cm) stenoses of the infrarenal aorta
rtic stenosis with atheroembolic disease
edium length (2-4) stenoses of the infrarenal aorta, with
moderate to severe atherosclerosis of the aorta otherwise
ac stenoses 5-10 cm in length
4
ac stenoses greater than 10 cm in length
ronic iliac occlusions greater than 4 cm in length after
thrombolytic therapy
tensive bilateral aortoiliac atherosclerotic disease
rtic or iliac stenoses in patients with AAA or other lesions
requiring aortic or iliac surgery
iliac artery; EIA, external iliac artery.nd S
type
Sh
Ili
type
2-
Ili
type
Lo
Ao
M
Ili
type
Ili
Ch
Ex
Aowhether the study reported a consecutive series, a prospec-
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exclusion, indication for intervention, detailed description
of complications, and mortality. Methodologic quality was
not an exclusion criterion.
Data extraction. Data were extracted by two authors
(V.J. and K.Y.) independently using a standardized form.
In case of disagreement, repeat review of the studies in
question was performed. If recorded, the following infor-
mation was extracted from the included studies: publica-
tion year, country of origin, number of patients, and study
design. In addition, the following data were extracted:
patient characteristics, morphology of aortoiliac occlusive
lesions, detailed method of intervention, technical success,
clinical success, mortality and morbidity rates, and primary,
primary-assisted and secondary patency rates. If the study
described combined results for limited and extensive
AIOD, only data for extensive disease were extracted, if
possible.
Any discrepancies in judgment considering search strat-
egy, selection of papers, quality assessment, or data extrac-
tion were resolved by discussion between the authors. Final
decisions were made after consensus was reached.
RESULTS
The search identified 488 articles of which 73 studies
were selected for full text review based on title and abstract.
Fifty-four studies were excluded after full text review. Study
flow and reasons for exclusion are presented in the Figure.
Four technical reports, three small case series and one
review article were excluded.12-19 Two studies reported on
similar databases and were excluded.20,21 Twenty-four
studies reported solely on localized AIOD or reported on a
different study group and were also excluded. Thirty-one
studies reported combined results of localized and exten-
sive AIOD. As specific results for extensive AIOD could not
be retrieved from 20 studies, these were excluded. Nine-
teen studies were included in the systematic review.22-40
Four studies originated from two study groups but con-
sidered different patient groups and were not exclu-
ded.25,31,33,37 The chance adjusted inter-reviewer agree-
ment for study eligibility () was 0.76.
Fifteen studies used TASC classification to describe
Fig. Flow chart illustrating study selection.aortoiliac lesions, while in two studies SCVIR classificationwas used.28,38 Two studies did not use a classification
system,32,34 but sufficiently described the morphology of
aortoiliac lesions in their patient group to consider them
“extensive”. In total 1711 patients were evaluated of
which 1329 patients had extensive AIOD. From eight
studies, specific data on extensive AIOD could be deri-
ved,22,23,25,30,33,35,36,39 while 11 studies reported com-
bined results for extensive and localized AIOD. Three
studies specifically reported on aortic occlusive disease.32-34
Eleven studies were performed in Europe, seven in the
United States, and one in Korea.
Study quality. Results of the methodologic quality as-
sessment are presented in Table II. No prospective studies or
randomized trials were found. All studies reported results
from a single center. In amajority of the studies, selection bias
could not be excluded. Patient selection varied between the
studies: endovascular treatment of extensive AIOD was per-
formed as treatment of choice,30,31,36,39 or because patients
were unfit for open surgical repair.22,26,29,32,37 Some studies
excluded patients with disease extending into the common
femoral artery or aorta,23,24 while other studies excluded
patients with extensive calcified lesions.30 Also, the use of
hybrid techniques (combining surgery with endovascular
techniques) varied between the studies. Because of the heter-
ogeneity of the studies, pooling of data was not considered
appropriate.
Methods of intervention. Endovascular treatment of
extensive AIOD was mostly performed using percutaneous
techniques. In two studies, an open technique was used for
endovascular access.22,25 Additional surgical outflow pro-
cedures, including endarterectomy of the common femoral
artery, femoro-femoral bypass, or femoro-popliteal bypass,
were performed in 10 studies.23,26,27,30,31,34-37,40 In one
study, this was performed in a second interventional ses-
sion.23 Traditionally, a transfemoral approach was used for
endovascular therapy. In some patients, a transbrachial
access was used for additional endovascular access.24,25,30-32,34
Moise et al used the left brachial artery as standard access
point in all patients because of the ease of engaging both
iliac systems via this route.33
To facilitate recanalization and angioplasty or stenting
of stenosed or occluded arterial segments intra-arterial
thrombolysis was used in selected patients by some au-
thors.31,33,34,36 Incidentally, debulking of thrombus in
case of occlusion or severe long stenoses has been per-
formed using a excimer laser catheter.23,38 Primary stenting
was performed in most studies, while selective placement of
stents was performed in four studies only.27,33,36,39 Indi-
cations for stent placement in these studies were occlusions,
complex or large plaques, or unsatisfactory technical results
after balloon angioplasty alone. Stenting was performed
using a variety of bare stents or endografts. In general,
balloon-expandable stents were used in heavily calcified
lesions, while self-expanding stents were preferred in longer
noncalcified lesions.
Outcomes. Outcomes are depicted in Table III.
Technical success was reported in all studies and was
mostly defined as less then 30% residual diameter stenosis
s fulfil
charac
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than 5 or 10 mm Hg.22-28,32,35-40 In addition, a marked
reduction of the translesion pressure gradient compared with
Table II. Quality assessment of included studies
First author Year
Study
population
No
selection
bias
Method of
intervention
Descri
of outc
Nyman 2000    
Scheinert 2001    
Ali 2003    
Greiner 2003    
Rzucidlo 2003    
Domanin 2005    
Lagana 2006    
Ballzer 2006    
De Roeck 2006    
Park 2007    
Piffaretti 2007    
Bjorses 2008    
Chang 2008    
Gandini 2008    
Hans 2008    
Sixt 2008    
Sharafuddin 2008    
Kashyap 2008    
Moise 2009    
Quality assessment list of the included studies, depicting whether the article
separate quality score was determined based upon the description of study
Table III. Summary of data obtained from the included s
First author Year N N eAIOD
Age,
mean
y
Male
(%)
Techn
succ
(%
Nymana 2000 30 21 61 43 93
Scheinerta 2001 212 212b 60 78 90
Ali 2003 22 22 63 91 95
Greinera 2003 25 23 NS 60 86
Rzucidloa 2003 34 29 63 62 100
Domanina 2005 42 28 60 71 100
Laganaa 2006 19 11 66 63 95
Ballzer 2006 89 89 64 72 97
De Roecka 2006 38 26 59 89 97
Park 2007 218 66 64d 95 98
Piffaretti 2007 43 43 66 70 100
Bjorsesa 2008 173 88 64 46 99
Chang 2008 171 171 67 62 98
Gandinia 2008 138 138c 63 75 99
Hans 2008 40 40 59 60 95
Sixt 2008 375 179 63 80 96
Sharafuddina 2008 66 47 64 70 94
Kashyapa 2008 83 65 64 57 96
Moise 2009 31 31 65 29 93
N eAIOD, Number of patients with extensive aortoiliac occlusive disease (A
in the article.
aCombined report of limited and extensive AIOD.
bSCVIR classification: class III in 46 patients and class IV in 166 patients.
cSCVIR classification: class III in 71 patients and class IV in 79 patients.
dCombined results of limited and extensive AIOD.
eMeasured after one year follow-up.
fOnly major morbidity.
gfor stenoses and occlusions respectively.pretreatment valueswas also considered as technical success byNyman et al.34 Reported technical success ranged from 86%
to 100%. Most common reasons for technical failure were
inability to cross an occluded arterial segment, thrombosis
Independent
observers
No selective
loss to
follow-up
Description of
confounders
Quality score of
description of study
characteristics
   7
   9
   8
   6
   9
   9
   8
   9
   9
   7
   7
   10
   9
   9
   8
   7
   7
   6
   8
led the requirements as stated in the Methods section.   yes,   no. A
teristics. Maximum score was 12.
s
Clinical
improvement
(%)
Mortality
(%) 30 d
Morbidity
(%)
Follow-up,
mean mo
Length of
stay,
mean d
83 6.7 27 19/11g 2median
88 0 11 31 4.8
100 0 NS 12 NS
88 0 NS 16 NS
97 3 3 21max NS
100 0 12 NS NS
NS 0 21 20 3.2
92 0 16 36 NS
100 3 5 26 NS
NS 0 6d 30d NS
NS 0 5f 32 4.1
86 1.2 14 36 NS
92 2.3 22 24median 2median
99 0 7 108 NS
NS 0 15 32 1
70e 0 NR NS NS
NS 4.5 14 37median NS
NS 3.6 16 21 NS
NS 0 45 12 3median
;NR, data not retrievable for patients with extensive AIOD;NS, not statedption
omestudie
ical
ess
)
d
IOD)after recanalization, or iliac artery rupture.
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postintervention or at first follow-up visit. Clinical symp-
toms improved in 83% to 100% of the patients. In one
study, change of clinical symptoms for individual patients
was reported only after 1-year follow-up, improvement was
recorded in 70% of the patients.39
Mortality was reported in all included studies. In 12
studies, no perioperative or 30-day mortality was found,
while seven studies reported a mortality rate ranging from
1.2% to 6.7% (Table II). In addition tomortality, morbidity
rates could be derived from 16 studies. One study only
reported major complications.36 Reported morbidity rate
ranged widely between the other 15 studies (range, 3% to
45%). Most common reported complications were access
site hematomas (reported in 7 studies, range, 4% to 17%),
distal embolization (reported in 10 studies, range 1% to
11%), arterial dissections (reported in 7 studies, range, 2%
to 5%), pseudoaneurysms (reported in 10 studies, range
0.5% to 3%), and iliac artery or aortic ruptures (reported in
7 studies, range 0.5% to 3%). The majority of complications
could be treated using percutaneous or noninvasive tech-
niques. Arterial dissections and ruptures were mostly
treated by (covered) stent placement, while distal em-
bolization was treated by aspiration or thromboly-
sis.24,25,27,28,30,40 Surgical repair was required to treat less
then half of the patients with pseudoaneurysms and a few of
the patients with access site hematomas or vessel rupture.
Length of stay was reported by seven studies and ranged
from 1 to 4.8 days.
Patency results are presented in Table IV. One-year
Table IV. Primary and secondary patency rates
First author Year
1 year 2 year
PP (%) SP (%) PP (%) SP (%
Nyman 2000 97 100a
Scheinert 2001 84 88 81 88
Ali 2003 84 95b
Greiner 2003 91a 65a
Rzucidlo 2003 70 88
Domanin 2005 70 88
Lagana 2006 89 100
Ballzer 2006
De Roeck 2006 94 100 89 94
Park 2007 C 94
D 93
C 97
D 94
Piffaretti 2007 92 86
Bjorses 2008 97 100 88 97
Chang 2008
Gandini 2008 95 97 93 96
Hans 2008
Sixt 2008 C 86
D 85
C 98
D 98
Sharafuddin 2008
Kashyap 2008 90 97 82 97
Moise 2009 85 100
C, Results for patients with TASC type C lesions; D, results for patients wit
aprimary assisted patency.
blimb salvage rate.primary and secondary patency ranged from 70% to 97%and 88% to100%, respectively. Four- or 5-year primary
and secondary patency rates could be derived from eight
studies and ranged from 60% to 86% and 80% to 98%,
respectively.
Two studies retrospectively compared endovascular
therapy and open surgical reconstruction for extensive
AIOD.30,31 Choice of treatment was performed by the
surgeon or interventionist treating the patient. Patients
who had severe calcifications were not considered for
stenting by Hans et al, but no further considerations for
treatment allocation were mentioned. Patients undergo-
ing endovascular therapy were older but had similar
clinical variables as patients undergoing surgical repair.
Mortality did not differ between the groups in both
studies, as did morbidity in the study of Kashyap et al.
Hans et al reported substantial perioperative morbidity
in the open surgery group (pulmonary complications in
13%, cardiac 9%, other systemic complications in 16%
and 6% local wound complications).30 In the endovascu-
lar group, intraprocedural complications occurred in
10%, which could all be solved with percutaneous tech-
niques, while two patients experienced access-related
complications which could be treated conservatively.
Length of stay was measured by Hans et al and was
significantly shorter for the endovascular group (1 vs 7
days). Both studies reported significantly lower long-
term primary patency for endovascular therapy (69% vs
93%, P  .01330 and 74% vs 93%, P  .002 31). Second-
ary patency did not differ significantly, however (89% vs
3 year 4 year 5 year
PP (%) SP (%) PP (%) SP (%) PP (%) SP (%)
78 86 76 85 66 80
90 96
89 94 77 94 77 94
C 94
D 74
C 97a
D 85a
C 78
D 74
C 74a
D 85a
81
83 95 74 91 65 83
60 98
91 94 88 93 86 90
69 89
81 94a
74 95
66 90
C type D lesions; PP, primary patency; SP, secondary patency.)
h TAS100%, P  .05 30 and 96% vs 96%31).
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Endovascular therapy currently has been firmly estab-
lished as the treatment of choice for localized aortoiliac
occlusive disease. The role of endovascular techniques in
the management of extensive and complex aortoiliac dis-
ease, on the other hand, is still controversial. For these
patients, the TASC multidisciplinary guidelines recom-
mend operative reconstruction, unless operative risk is pro-
hibitive.8 Long-term patency rates of aortobifemoral
bypass graft or aortoiliac endarterectomy are excellent
(85%-92%), with modest operative mortality.1-4 However,
perioperative morbidity of surgical revascularization is sub-
stantial, while the time-period before return to normal
activities and the effects on sexual function are also impor-
tant to consider. Systemic or major morbidity rates are
reported up to 10%, with overall morbidity 11% to 32%.
Endovascular treatment is a less invasive management
option, potentially reducing morbidity. Moreover, when
the outcome does not meet expectations, patients may still
be referred for conventional surgical therapy without much
“lost”. The development of new technologies and tech-
niques has led to increasing use of endovascular techniques
in the treatment of extensive AIOD. A systematic search
revealed 19 clinical studies reporting on endovascular treat-
ment of extensive AIOD. In this heterogenic group of
studies, selected patients with extensive AIOD could be
treated using endovascular techniques with good technical
success rates. Despite the use of various endovascular tech-
niques, technical success was reported over 90% in all but
one study.
There was a wide range in reported complication rates.
This variation may be caused by varying interventional
techniques and different study populations, sometimes
with multiple comorbidities. Furthermore, the retrospec-
tive nature of the studies may have led to under reporting.
Although reported complication rates were considerable,
most complications could be treated percutaneously or
conservatively. The use of multiple access sites, perfor-
mance of additional surgical revascularization procedures,
and high incidence of comorbidities in most studies may
have increased the risk for complications. The high mor-
bidity rate reported by Moise et al (45%) is partly due to
access site complications at the brachial artery occurring in
5 of 31 patients.33 In total, the majority of reported com-
plications were technical, such as iliac artery injury, distal
embolization, and access site complications. Growing ex-
perience and advances in development of endovascular
devices will probably reduce these complications.
Long-term primary patency rates following endovascu-
lar treatment cannot yet compete with those reported for
open reconstructive surgery. Nevertheless, reinterventions
following loss of primary patency after endovascular ther-
apy could be performed using percutaneous techniques in
the majority of patients, obtaining secondary patency rates
of 80% to 98%. Hereby, the minimal invasive character of
the intervention has been maintained, with avoidance of
surgery with concomitant risks. It needs to be consideredthat only one study reported a mean follow-up of more
than 5 years.
Several factors that may influence long-term patency
after endovascular therapy of AIOD were analyzed in the
included studies, including stent placement, lesion mor-
phology, and outflow. The Dutch Iliac Stent Trial, a ran-
domized study comparing primary stenting of AIOD with
selective stent placement, has shown similar late patency for
both groups, with lower costs in the selective stenting
group.41 Despite this, primary stenting was preferred in
most studies for extensive aortoiliac lesions. Arguments in
favor of primary stent placements were that stent deploy-
ment without predilatation (direct stenting), not only re-
duces the risk of vessel rupture, but also decreases the risk of
distal embolism.23,30,32,34 Three studies analyzed the influ-
ence of stent placement on long-term patency. Neither
Domanin et al27 nor Pifaretti et al36 found a statistically
significant difference in primary patency between patients
receiving stent grafting or treated by balloon angioplasty
alone. In contrast, Sixt et al39 found that the 1-year primary
patency rate after stenting was significantly better com-
pared to balloon angioplasty alone.
Several studies analyzed the influence of lesion mor-
phology on long-term results. One study found that pri-
mary and assisted primary patency rates were significantly
lower for iliac artery occlusions over 10 cm in length
compared with those for occlusions less than 10 cm in
length.38 On the other hand, none of the other studies
found a significant difference between localized vs extensive
aortoiliac disease.24,26,31,35,39,40 Distal outflow may influ-
ence primary patency as is pointed out by several au-
thors.29,30,39 To improve outflow, infrainguinal revascular-
ization was performed in a small majority of the studies.
Aside from endovascular therapy, other alternatives for
open surgery are axillobifemoral bypass or (robot-assisted)
laparoscopic aortic surgery. Operative morbidity is reduced
after axillobifemoral bypass, but durability is also substan-
tially lower.42,43 Laparoscopic aortic surgery without or
with robot-assistance has been developed as a minimal
invasive option for AIOD, reducing operative trauma and
facilitating quicker ambulation.44-46 Long-term follow-up
results are scarce, however, and more data are required to
define the value of (robot-assisted) laparoscopic aortic sur-
gery.
Several limitations to our study need to be addressed.
To retrieve recent literature we have restricted our system-
atic search to studies published after January 2000. Due to
this time constriction, relevant studies could have been
missed by our search. However, the multidisciplinary
TASC guidelines, published in 2007, already considered
relevant literature to that date. The aim of this systematic
review was to retrieve relevant data not yet considered in
TASC guidelines. Furthermore, the majority of the studies
included in this review were published in the last 2 years.
The TASC classification for lesion morphology was
used by the far majority of studies published on AIOD in
the last decade. In some studies, however, other or no
classification systems are used. To achieve more studies,
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this review, inevitably leading to increased heterogeneity
between the included studies and decreased accuracy for
determining extensive AIOD.
Most studies included in this systematic review origi-
nate from tertiary referral centers or centers of excellence
reporting on selected patients. The results reported by
these studies may not be applicable to other centers. In
several studies, endovascular therapy was not the primary
treatment for extensive AIOD, but offered to patients with
significant comorbidities unsuitable for surgical repair. Fur-
thermore, only selected patients suitable for endovascular
treatment were reported, while exclusion criteria for endo-
vascular treatment were often not mentioned. All studies
were retrospective and most included a small number of
patients, precluding adequate subgroup analysis and limit-
ing the value of statistical analysis. Because of these short-
comings, it is difficult to make recommendations regarding
technique or patient selection. Despite this, the results
from the included studies suggest that most occlusions and
long stenoses can be recanalyzed without the need for
thrombolysis or laser catheters. Next, in complex lesions,
stent placement is mostly preferred over balloon angio-
plasty alone. Regarding patient selection some authors
point out that recanalization of heavy calcified occlusions
can be challenging, with a higher risk of vessel rupture
during dilatation.24,25,30 For these lesions, the use of cov-
ered stent grafts could prove advantageous.24,25 However,
data from controlled trials is necessary to support these
opinions.
The TASC criteria provide a classification system,
which can be used to compare outcomes between stud-
ies. However, the recommendations of the TransAtlantic
Inter-Society Consensus seem in need of reconsidera-
tion. Although it is not yet clear if all AIOD lesions are
amendable for endovascular therapy, over 1000 patients
included in this review have been successfully treated
with endovascular techniques, while according to TASC
guidelines surgical revascularization should have been
the preferred treatment.
In conclusion, endovascular treatment of extensive
AIOD can be performed safely and effectively in multiple
centers worldwide. In the hands of experienced interven-
tionists, technical success rates are high with modest mor-
bidity. Although primary patency rates of endovascular
techniques were inferior to those of open revascularization,
reinterventions could often be performed percutaneously.
Secondary patency rates are comparable to surgical repair,
but length of follow-up after endovascular techniques is still
limited. Larger and prospective studies are required to
confirm the potential advantages of endovascular treatment
over surgery for extensive AIOD. Nevertheless, with con-
tinuing developments in endovascular techniques and de-
vices as well as growing experience of interventionalists,
indications for endovascular treatment of extensive AIOD
will be broadened.AUTHOR CONTRIBUTIONS
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